Health-care companies slid after signs of stress in UnitedHealth Group's business.
The largest U.S. insurer by enrollees cut its growth projections, citing hitches with its key Medicare business.
Among other insurers who rely on Medicare demand, Humana shares sold off.
Shares of Eli Lilly soared after the American drug maker's latest glucagon-like peptide pill candidate showed efficacy in a clinical trial on diabetes patients. Investors have long awaited a pill version of the popular obesity-drug injections, and Lilly's pill compared favorably to Novo Nordisk's blockbuster Ozempic product when it came to patients' weight loss.
Shares of Novo Nordisk plunged.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
April 17, 2025 17:16 ET (21:16 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.